OBJECTIVE: To determine the prevalence of low and high antiretroviral (ARV) plasma levels and to analyze correlation between ARV concentrations and the appearance of therapeutic failure and toxicity. METHODS: The authors present here a study evaluating antiretroviral plasma concentrations in HIV infected children on nonnucleoside reverse transcriptase inhibitors and protease inhibitors based therapy. The authors carried out a multicentre, cross-sectional study, including HIV-infected children from five large Hospitals in Madrid, Spain. Clinical, haematological, biochemical and immuno-virological parameters were assessed. Antiretroviral plasma trough levels were performed using a validated high performance liquid chromatography method. RESULTS: Between April 2006 and April 2008, 129 children were enrolled in the present study, with median treatment duration of 39.2 months. 25.5% of the non-nucleoside reverse transcriptase inhibitors levels were low and 17.6%, high. 27.9% percent of the protease inhibitors levels were low and 12.5%, high. A correlation was found among adequate or high levels of antiretrovirals and normal CD4 percentage and low viral load. Lopinavir/ritonavir plasma levels were correlated with an increase in lipodystrophy. Patients with Tanner stage 1 presented the lowest ARV plasma levels. Full adherence was reported for all the participants by a questionnaire. CONCLUSION: Many HIV-infected children show ARV plasma levels out of the therapeutic range which demands a child-adjusted approach. However, larger studies are urgently needed in pediatric populations to define optimal reference values.
OBJECTIVE: To determine the prevalence of low and high antiretroviral (ARV) plasma levels and to analyze correlation between ARV concentrations and the appearance of therapeutic failure and toxicity. METHODS: The authors present here a study evaluating antiretroviral plasma concentrations in HIV infectedchildren on nonnucleoside reverse transcriptase inhibitors and protease inhibitors based therapy. The authors carried out a multicentre, cross-sectional study, including HIV-infectedchildren from five large Hospitals in Madrid, Spain. Clinical, haematological, biochemical and immuno-virological parameters were assessed. Antiretroviral plasma trough levels were performed using a validated high performance liquid chromatography method. RESULTS: Between April 2006 and April 2008, 129 children were enrolled in the present study, with median treatment duration of 39.2 months. 25.5% of the non-nucleoside reverse transcriptase inhibitors levels were low and 17.6%, high. 27.9% percent of the protease inhibitors levels were low and 12.5%, high. A correlation was found among adequate or high levels of antiretrovirals and normal CD4 percentage and low viral load. Lopinavir/ritonavir plasma levels were correlated with an increase in lipodystrophy. Patients with Tanner stage 1 presented the lowest ARV plasma levels. Full adherence was reported for all the participants by a questionnaire. CONCLUSION: Many HIV-infectedchildren show ARV plasma levels out of the therapeutic range which demands a child-adjusted approach. However, larger studies are urgently needed in pediatric populations to define optimal reference values.
Authors: David Back; Giorgio Gatti; Courtney Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo-Federico Perno Journal: AIDS Date: 2002-03 Impact factor: 4.177
Authors: D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: C V Fletcher; R C Brundage; R P Remmel; L M Page; D Weller; N R Calles; C Simon; M W Kline Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: Félix Gutiérrez; Sergio Padilla; Mar Masiá; Andrés Navarro; Juan Gallego; Ildefonso Hernández; José Manuel Ramos; Alberto Martin-Hidalgo Journal: Antivir Ther Date: 2004-02
Authors: Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong Journal: Can J Hosp Pharm Date: 2012-03
Authors: Roberta Prinapori; Raffaella Rosso; Antonio Di Biagio; Franca Miletich; Elisa Furfaro; Lucia Taramasso; Francesca Ginocchio; Vania Giacomet; Loredana Nulvesu; Maria Pia Sormani; Irene Schiavetti; Alessio Signori; Laura De Hoffer; Claudio Viscoli Journal: Indian J Pediatr Date: 2013-09-07 Impact factor: 1.967